Development of technologies for evaluation of antibody response following Coronavirus Infection vs Vaccination to identify immune correlates of protection
Document text
Principal Investigator: Hana Golding Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2020 Award: $160,000 Funding agency: National Institute of Allergy and Infectious Diseases The emergence of the Coronavirus (SARS-CoV-2) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or SARS-CoV-2 infection in animals or humans. It is important to identify and understand immune markers that are reasonably likely to predict clinical benefit and that can facilitate evaluation of vaccine and therapeutic candidates, including: I. Do different vaccine platforms elicit similar or different antibody epitope repertoires, antibody isotypes, antibody affinity and durability in human’s vs animals? II. What are the correlates of protection against SARS-CoV-2: Total antibody binding to specific antigenic regions within spike protein? antibody affinity? antibody isotype? antibody epitope diversity? III. Is the quantity, quality (epitopes and affinity) and durability of antibodies generated by SARS-CoV-2- vaccination is similar or different than those of antibodies found in post-infection (in acute and convalescent) sera? To address these gaps, we will develop advanced technologies, including whole genome phage display library (GFPDL) and SPR for the new Coronavirus (SARS-CoV-2) for in-depth analysis of immune responses following vaccination and SARS-CoV-2 infection in animal models or humans. Terms: <2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Acute><Address><Affinity><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Affinity><Antibody Diversity><Antibody Response><Antigenic Determinants><Binding><Binding Determinants><Blood Plasma><CoV emergence><Coronaviridae Infections><Coronavirus Infections><Disease><Disorder><Epitopes><Evaluation><Genome><Human><IgG><Immune><Immune Markers><Immune response><Immunes><Immunoglobulin G><Immunologic Markers><Immunological response><Infection><Kinetics><Knowledge><Libraries><Modern Man><Molecular Interaction><Phage Display><Plasma><Plasma Serum><Proteins><Regimen><Reticuloendothelial System, Serum, Plasma><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Severe acute respiratory syndrome coronavirus 2><Technology><Therapeutic><Vaccination><Vaccines><Wuhan coronavirus><antigen antibody affinity><clinical predictors><coronavirus emergence><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><entire genome><full genome><host response><immune-based biomarkers><immunological biomarkers><immunological markers><immunoresponse><medical countermeasure><model of animal><model organism><nCoV><new CoV><new coronavirus><novel CoV><novel coronavirus><polyclonal antibody><social role><tech development><technology development><therapeutic candidate><vaccine candidate><vaccine evaluation><vaccine screening><vaccine testing><whole genome>